Skip to main content

Kepler Capital Remains a Buy on Smith & Nephew (SN)

Tipranks - Tipranks - Wed Mar 4, 8:06PM CST

Kepler Capital analyst Christophe dombu maintained a Buy rating on Smith & Nephew on March 2 and set a price target of p1,462.00. The company’s shares closed yesterday at p1,313.00.

Claim 70% Off TipRanks Premium

dombu covers the Healthcare sector, focusing on stocks such as Smith & Nephew, Nyxoah, and Basilea Pharmaceutica. According to TipRanks, dombu has an average return of -1.8% and a 53.92% success rate on recommended stocks.

Currently, the analyst consensus on Smith & Nephew is a Moderate Buy with an average price target of p1,490.57, which is a 13.52% upside from current levels. In a report released on March 2, Morgan Stanley also maintained a Buy rating on the stock with a p1,482.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Smith & Nephew’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of p2.99 billion and a net profit of p295.65 million. In comparison, last year the company earned a revenue of p2.83 billion and had a net profit of p214 million

Read More on GB:SN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).